Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer’s Disease

Kim H, Lee J, Qian A, Ji YR, Zhang R, Hu Q, Williams CK, Chuang HY, Smalley MD, Xu Y, Gao L, Mayo MC, Zhang[...]

Hybrid strategy of coronary atherosclerosis characterization with T1-weighted MRI and CT angiography to noninvasively predict periprocedural myocardial injury

Matsumoto H, Higuchi S, Li D, Tanisawa H, Isodono K, Irie D, Ohya H, Kitamura R, Kaneko K, Nakazawa M, Suzuki K, Komori Y, Hondera[...]

Automated Deep Learning Phenotyping of Tricuspid Regurgitation in Echocardiography

Vrudhula A, Vukadinovic M, Haeffele C, Kwan AC, Berman D, Liang D, Siegel R, Cheng S, Ouyang D. Automated Deep Learning Phenotyping of Tricuspid Regurgitation[...]